Modulating trained immunity has therapeutic potential in a broad range of diseases, including infectious diseases, autoinflammatory disorders, cancer, atherosclerosis, and organ transplantations.5–7,9 Our data show that acid ceramidase, and ceramide metabolism, represent promising therapeutic targets that can be explored to control trained immunity. The gene discussed is ASAH1; the disease is atherosclerosis.